STOCK TITAN

Femasys Inc. - $FEMY STOCK NEWS

Welcome to our dedicated page for Femasys news (Ticker: $FEMY), a resource for investors and traders seeking the latest updates and insights on Femasys stock.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Femasys's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Femasys's position in the market.

Rhea-AI Summary

Femasys announced that CEO Kathy Lee-Sepsick met with the White House’s Office of Science and Technology Policy to discuss the Cancer Moonshot initiative and the company's diagnostic tool, FemCerv. FemCerv is designed for the detection of cervical cancer, allowing for the collection of an uncontaminated sample virtually pain-free. Femasys aims to expand its cancer diagnostic tools to include an endometrial sampler for uterine cancer. Additionally, the company will showcase its products at the 2024 ACOG Annual Clinical and Scientific Meeting in San Francisco from May 17-19.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.55%
Tags
none
-
Rhea-AI Summary

Femasys CEO Kathy Lee-Sepsick met with the White House’s Gender Policy Council to discuss the company's reproductive health products and the future of women's health in the U.S. The meeting supported the President's Executive Order on Advancing Women’s Health Research and Innovation, highlighting funding needs for women’s healthcare initiatives. Femasys, an Atlanta-based biomedical company, offers innovative in-office therapeutic and diagnostic products. The company will display its products, including FemBloc® and FemaSeed®, at the ACOG Annual Meeting in San Francisco from May 17-19, 2024.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.01%
Tags
none
-
Rhea-AI Summary

Femasys Inc. (NASDAQ: FEMY) announces financial results for Q1 2024, highlighting positive topline data for FemaSeed infertility treatment, commercial procedures, appointment of Richard Spector as Chief Commercial Officer, and initiation of pivotal trial for FemBloc. The company is well-positioned to commercialize its infertility portfolio, with cash to fund operations into H2 2025. Financially, R&D expenses increased, sales decreased, and net loss grew, but the company believes its cash and equivalents will suffice. Current assets, liabilities, and stockholders' equity are detailed in the PR.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-8.63%
Tags
Rhea-AI Summary

Femasys Inc. (Nasdaq: FEMY) announces the expansion of its commercial management team, adding experienced professionals to drive strategic initiatives and launch efforts at the 2024 ACOG Meeting. The team will focus on the infertility portfolio, led by FemaSeed®, a cost-effective and safe approach for artificial insemination. The company aims to address the record-low birth rates in the U.S. by providing innovative solutions to women's healthcare needs.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.19%
Tags
management
-
Rhea-AI Summary
Femasys CEO and Founder Kathy Lee-Sepsick meets with Members of Congress to raise awareness of the company and discuss women's healthcare initiatives. The company focuses on addressing unmet needs of women with a portfolio of innovative products. President Biden's executive order for women's health initiatives has spurred interest in Femasys' solutions. The company offers minimally-invasive reproductive products and is developing a permanent birth control solution called FemBloc. Femasys recently announced positive topline data from its FemaSeed pivotal trial, showing a 24% pregnancy rate in women with male factor infertility.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.77%
Tags
none
-
Rhea-AI Summary
Femasys Inc. secures capital after FDA clearance of FemaSeed® to support commercial initiatives, with positive trial data and key appointments. Financially, R&D expenses increased, while sales decreased, resulting in a net loss, but the company expects to fund operations into 2H 2025.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
10.97%
Tags
Rhea-AI Summary
Femasys Inc. (NASDAQ: FEMY) CEO Kathy Lee-Sepsick and CMO James Liu will discuss infertility treatment options, including FemaSeed®, in a virtual Fireside Chat with Jones Trading Analyst Catherine Novack. The event will focus on ART trends, FemaSeed's role, and challenges like rising IVF costs.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.44%
Tags
none
-
Rhea-AI Summary
Femasys Inc. (NASDAQ: FEMY) announces positive topline data from its FemaSeed Localized Directional Insemination pivotal trial, showing a 24% pregnancy rate in women with severe male factor infertility. This rate is more than double the historic IUI rate, positioning FemaSeed as a cost-effective first-line treatment option. The majority of successful pregnancies occurred after the first FemaSeed procedure, with no new safety concerns reported. With FDA clearance and funding secured until 2025, Femasys is set to launch FemaSeed in the U.S. in the first half of this year.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-10%
Tags
none
-
Rhea-AI Summary
Femasys Inc. (NASDAQ: FEMY) announces CEO Kathy Lee-Sepsick and CMO James Liu will join Jones Trading Analyst Catherine Novack in a discussion on infertility treatment options, including FemaSeed®. The event will focus on current trends in assisted reproductive technology and challenges like rising IVF costs.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.24%
Tags
conferences
Rhea-AI Summary
Femasys Inc. announces the first commercial procedure using FemaSeed, an alternative to IVF, aiming to reshape female infertility management. Top-line pivotal data expected in Q1 2024 amidst ongoing uncertainty post-Alabama Supreme Court ruling.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-11.27%
Tags
none
Femasys Inc.

Nasdaq:FEMY

FEMY Rankings

FEMY Stock Data

26.89M
19.87M
7.64%
6.42%
7.88%
Surgical and Medical Instrument Manufacturing
Manufacturing
Link
United States of America
SUWANEE

About FEMY

our experienced management team has over 200 years of collective industry experience with extensive focus in medical devices. the pioneering and collaborative efforts of the management team have created an organization that strives for integrity in all actions, innovation in development activities, excellence in operations, and the highest quality products. the team is complemented by world-class medical advisors. our products have been organically conceived, researched and developed by the company and all manufacturing activities are conducted to ensure compliance with the u.s. food and drug administration (fda) per the requirements of 21 cfr 820, as well as iso 13485. femasys has achieved significant milestones to date, including numerous issued patents and filings, recruitment of a team of experts, clearance of multiple regulatory filings by the u.s. food and drug administration (fda), european union, canada, and japan with other select countries in process. making a difference in t